Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Connect Biopharma Holdings (CNTB) Shares Outstanding (Weighted Average) (2023 - 2025)

Connect Biopharma Holdings' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $55.5 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) changed 0.49% year-over-year to $55.5 million; the TTM value through Sep 2025 reached $55.5 million, changed 0.49%, while the annual FY2024 figure was $55.2 million, 0.27% changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $55.5 million at Connect Biopharma Holdings, roughly flat from $55.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $55.5 million in Q3 2025 and bottomed at $55.1 million in Q4 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $55.2 million (2024), against an average of $55.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 0.27% in 2024 before it grew 0.64% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $55.1 million in 2023, then grew by 0.27% to $55.2 million in 2024, then increased by 0.56% to $55.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Shares Outstanding (Weighted Average) are $55.5 million (Q3 2025), $55.5 million (Q2 2025), and $55.4 million (Q1 2025).